Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
2.610
+0.080 (3.16%)
At close: May 5, 2026, 4:00 PM EDT
2.680
+0.070 (2.68%)
After-hours: May 5, 2026, 7:14 PM EDT
Alaunos Therapeutics Employees
Alaunos Therapeutics had 1 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
1
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$5,000
Profits / Employee
-$4,282,000
Market Cap
6.21M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1 | 0 | - | 1 | 0 |
| Dec 31, 2024 | 1 | 0 | - | 1 | 0 |
| Dec 31, 2023 | 1 | -33 | -97.06% | 1 | 0 |
| Dec 31, 2022 | 34 | -7 | -17.07% | 34 | 0 |
| Dec 31, 2021 | 41 | -65 | -61.32% | 41 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 39 |
| Aptevo Therapeutics | 33 |
| BiomX | 20 |
| BioRestorative Therapies | 14 |
| Processa Pharmaceuticals | 12 |
| Purple Biotech | 10 |
| Immuron | 7 |
| Akari Therapeutics, | 6 |
TCRT News
- 1 day ago - Valion Bio Appoints Melinda Lackey as General Counsel - PRNewsWire
- 2 months ago - Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop - Benzinga
- 2 months ago - Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders - GlobeNewsWire
- 11 months ago - Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering - GlobeNewsWire
- 1 year ago - PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT) - GlobeNewsWire
- 2 years ago - Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives - GlobeNewsWire
- 2 years ago - Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS) - Benzinga
- 2 years ago - Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives - GlobeNewsWire